EWSR1, Polyclonal Antibody

RNA-binding protein EWS; EWS oncogene; Ewing sarcoma breakpoint region 1 protein; EWSR1; EWS

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit Ig

Rabbit

This EWSR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 623-652 amino acids from the C-terminal region of human EWSR1.

Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Vial Concentration: 0.5 (lot specific)

Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Small volumes of anti-EWSR1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

This gene encodes a multifunctional protein that is
involved in various cellular processes, including gene expression,
cell signaling, and RNA processing and transport. The protein
includes an N-terminal transcriptional activation domain and a
C-terminal RNA-binding domain. Chromosomal translocations between
this gene and various genes encoding transcription factors result
in the production of chimeric proteins that are involved in
tumorigenesis. These chimeric proteins usually consist of the
N-terminal transcriptional activation domain of this protein fused
to the C-terminal DNA-binding domain of the transcription factor
protein. Mutations in this gene, specifically a t(11;22)(q24;q12)
translocation, are known to cause Ewing sarcoma as well as
neuroectodermal and various other tumors. Alternative splicing of
this gene results in multiple transcript variants. Related
pseudogenes have been identified on chromosomes 1 and 14. [provided
by RefSeq].

Crown Antibodies

Immunofluorescence (IF), ELISA (EIA), Western Blot (WB)

WB~~1:1000

EWSR1 Antibody (C-term) western blot analysis in Hela cell line lysates (35ug/lane).This demonstrates the EWSR1 antibody detected the EWSR1 protein (arrow).

Fluorescent confocal image of Hela cell stained with EWSR1 Antibody (C-term). Hela cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.1%, 10 min), then incubated with EWSR1 primary antibody (1:25, 1 h at 37 degree). For secondary antibody, Alexa Fluor 488 conjugated donkey anti-rabbit antibody (green) was used (1:400, 50 min at 37 degree).Cytoplasmic actin was counterstained with Alexa Fluor 555 (red) conjugated Phalloidin (7units/ml, 1 h at 37 degree). Nuclei were counterstained with DAPI (blue) (10 ug/ml, 10 min).EWSR1 immunoreactivity is localized to Nucleus significantly.

68478

EWS RNA-binding protein 1

RNA-binding protein EWS

RNA-binding protein EWS

EWS  [Similar Products]

EWS_HUMAN

This gene encodes a multifunctional protein that is involved in various cellular processes, including gene expression, cell signaling, and RNA processing and transport. The protein includes an N-terminal transcriptional activation domain and a C-terminal RNA-binding domain. Chromosomal translocations between this gene and various genes encoding transcription factors result in the production of chimeric proteins that are involved in tumorigenesis. These chimeric proteins usually consist of the N-terminal transcriptional activation domain of this protein fused to the C-terminal DNA-binding domain of the transcription factor protein. Mutations in this gene, specifically a t(11;22)(q24;q12) translocation, are known to cause Ewing sarcoma as well as neuroectodermal and various other tumors. Alternative splicing of this gene results in multiple transcript variants. Related pseudogenes have been identified on chromosomes 1 and 14. [provided by RefSeq, Jul 2009]

EWS: an oncogenic RNA-binding protein. Might normally function as a repressor. Binds RPB3, SF1, calmodulin and RNA. Interacts with and regulated by Pyk2. Relocates from cytoplasm to ribosomes upon Pyk2 activation. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. 5 alternatively-spliced isoforms have been described.

Protein type: Oncoprotein; RNA-binding; Transcription, coactivator/corepressor

Chromosomal Location of Human Ortholog: 22q12.2

Cellular Component: nucleoplasm; cytoplasm; plasma membrane; nucleolus; nucleus

Molecular Function: calmodulin binding; identical protein binding; protein binding; zinc ion binding; RNA binding; nucleotide binding

Biological Process: transcription, DNA-dependent; regulation of transcription, DNA-dependent

Disease: Ewing Sarcoma

Lagirand-Cantaloube, J., et al. Biochem. Biophys. Res. Commun. 399(4):705-710(2010)
Kumagai, A., et al. Am. J. Clin. Pathol. 134(2):323-331(2010)
Aryee, D.N., et al. Cancer Res. 70(10):4015-4023(2010)
Riggi, N., et al. Genes Dev. 24(9):916-932(2010)
Olsen, J.V., et al. Cell 127(3):635-648(2006)

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.